Metagenomi, Inc. (NASDAQ:MGX) Receives $10.00 Average Target Price from Analysts

Posted by on May 16th, 2026

Shares of Metagenomi, Inc. (NASDAQ:MGX – Get Free Report) have been given an average rating of “Moderate Buy” by the five analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $9.00.

A number of analysts have issued reports on the company. Wall Street Zen downgraded Metagenomi from a “sell” rating to a “strong sell” rating in a report on Saturday. Wells Fargo & Company decreased their price target on Metagenomi from $12.00 to $9.00 and set an “overweight” rating for the company in a report on Tuesday. Finally, Weiss Ratings raised Metagenomi from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st.

Read Our Latest Stock Report on Metagenomi

Institutional Trading of Metagenomi

A number of institutional investors have recently bought and sold shares of MGX. Bank of America Corp DE lifted its holdings in shares of Metagenomi by 482.9% in the 4th quarter. Bank of America Corp DE now owns 21,113 shares of the company’s stock valued at $76,000 after purchasing an additional 17,491 shares during the last quarter. AQR Capital Management LLC purchased a new stake in shares of Metagenomi in the 1st quarter valued at about $119,000. Norges Bank purchased a new stake in shares of Metagenomi in the 2nd quarter valued at about $373,000. Marshall Wace LLP purchased a new stake in shares of Metagenomi in the 2nd quarter valued at about $222,000. Finally, Jane Street Group LLC purchased a new stake in shares of Metagenomi in the 2nd quarter valued at about $235,000.

Metagenomi Trading Down 3.0%

NASDAQ:MGX opened at $1.31 on Friday. The firm has a market cap of $49.32 million, a PE ratio of -0.57 and a beta of 0.63. The stock has a fifty day moving average price of $1.43 and a 200 day moving average price of $1.63. Metagenomi has a 12-month low of $1.25 and a 12-month high of $3.95.

Metagenomi (NASDAQ:MGX – Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). The business had revenue of $1.25 million for the quarter, compared to analysts’ expectations of $5.90 million. Metagenomi had a negative return on equity of 51.23% and a negative net margin of 384.61%. Equities analysts forecast that Metagenomi will post -2.19 EPS for the current year.

About Metagenomi

(Get Free Report)

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.

Featured Articles

Analyst Recommendations for Metagenomi (NASDAQ:MGX)

Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.